Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,588

Participants

Timeline

Start Date

April 30, 2000

Study Completion Date

February 29, 2004

Conditions
Osteoarthritis
Interventions
DRUG

glucosamine

DRUG

chondroitin sulfate

DRUG

glucosamine and chondroitin sulfate combined

DRUG

celecoxib

Trial Locations (16)

10003

Hospital for Joint Diseases, New York

15213

*University of Pittsburgh, Pittsburgh

19104

University of Pennsylvania, Philadelphia

44122

*Case Western Reserve University, Beachwood

60611

Northwestern University, Chicago

67214

*Arthritis Research and Clinical Centers, Wichita

84132

*University of Utah, Salt Lake City

85724

*University of Arizona Arthritis Center, Tucson

90048

*Cedars-Sinai Medical Center, Los Angeles

90095

*University of California, Los Angeles, Los Angeles

94110

*University of California San Francisco, San Francisco

98101

Virginia Mason Research Center, Seattle

35294-7201

University of Alabama at Birmingham, Birmingham

46202-5103

*Indiana University School of Medicine, Indianapolis

68198-3025

University of Nebraska Medical Center, Omaha

75231-4496

Arthritis Consultation Center, Dallas

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

US Department of Veterans Affairs

FED

NCT00032890 - Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) | Biotech Hunter | Biotech Hunter